HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY RECEIVING CALCIUM AND VITAMIN D

接受钙和维生素 D 的骨矿物质密度降低的 HIV 感染者

• 批准号: 7375239
• 负责人: THOMAS C MERIGAN
• 金额: $ 0.89万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375239
• 关键词: HIV; SUBJECTS; DECREASED; BONE; MINERAL; HIV; SUBJECTS; DECREASED; BONE; MINERAL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5163 is a phase II, randomized, double-blind, placebo-controlled study of the bisphosphonate alendronate for the treatment of HIV-associated decreased bone mineral density (BMD). Subjects will receive blinded study treatment for 48 weeks, in addition to a calcium/vitamin D supplement. This study will examine the effect of weekly alendronate on lumbar spine and hip BMD in HIV-infected subjects receiving stable antiretroviral therapy (ART), in addition to daily calcium/vitamin D supplement. The study also will assess the safety and tolerability of alendronate in this population.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。 A5163是双膦酸酯丙膦酸盐的II期，随机，双盲，安慰剂对照研究，用于治疗HIV相关的降低骨矿物质密度（BMD）。除了补充钙/维生素D补充剂外，受试者还将接受48周的盲研究治疗。这项研究将检查每周接受稳定抗逆转录病毒疗法（ART）的HIV感染受试者的腰椎和HIP BMD的影响，此外还有每日钙/维生素D补充剂。该研究还将评估该人群中alendronate的安全性和耐受性。